EMBLAC Stock Overview
Provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Embla Medical hf. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 29.60 |
| 52 Week High | DKK 0 |
| 52 Week Low | DKK 0 |
| Beta | 0.67 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -38.78% |
| Change since IPO | 202.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMBLAC | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -1.5% |
| 1Y | n/a | -8.9% | 3.5% |
Return vs Industry: Insufficient data to determine how EMBLAC performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EMBLAC performed against the UK Market.
Price Volatility
| EMBLAC volatility | |
|---|---|
| EMBLAC Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EMBLAC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EMBLAC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 4,000 | Sveinn Solvason | www.emblamedical.com |
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated.
Embla Medical hf. Fundamentals Summary
| EMBLAC fundamental statistics | |
|---|---|
| Market cap | DKK 13.15b |
| Earnings (TTM) | DKK 408.09m |
| Revenue (TTM) | DKK 5.48b |
32.2x
P/E Ratio2.4x
P/S RatioIs EMBLAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBLAC income statement (TTM) | |
|---|---|
| Revenue | US$819.70m |
| Cost of Revenue | US$313.15m |
| Gross Profit | US$506.55m |
| Other Expenses | US$445.45m |
| Earnings | US$61.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 61.80% |
| Net Profit Margin | 7.45% |
| Debt/Equity Ratio | 54.3% |
How did EMBLAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/28 06:58 |
| End of Day Share Price | 2024/07/01 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Embla Medical hf. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Benjamin Silverstone | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |